European Notebook: IPO Fever Comes To Europe; EMA Plans Adaptive Licensing Pilot Project
Pharmaceutical and biotech companies in Europe take heart from IPOs and new governmental schemes to improve patients’ early access to innovative medicines, while fresh calls are made for an integrated, over-arching European industrial strategy for the life sciences sector.
You may also be interested in...
EFPIA’s call for more integration in approaches to some areas of health care ahead of the European Parliamentary elections in May could benefit research.
With EMA deliberating about Avastin, Novartis and Roche have confirmed that they will appeal the €180.5 million fine imposed on them by Italy’s competition authority for anti-competitive behavior.
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.